Advances in the diagnosis and control of lymphomas

Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography‑computed tomography for the prediction of complete response and survival in patients with diffuse large B‑cell lymphoma

“…Current treatment approaches based on disease staging are not satisfactory for DLBCL, as these systems rely on data obtained prior to the current staging procedures, including PET-CT ( 3 ). Prognostic factors, including IPI score, have been evaluated in patients with high-grade lymphomas since the 1990s ( 4 , 5 ).…”

“…At present, the standard therapy for DLBCL includes administration of the anti-cluster of differentiation 20 monoclonal antibody, rituximab, which is typically added to chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), or other drugs in infusion with etoposide, prednisone, vincristine and cyclophosphamide (R-EPOCH) ( 2 ). However, first-line treatment fails in 20–40% of patients ( 3 ). At present, clinical scores, including the International Prognostic Index (IPI) ( 4 ) and the revised-IPI ( 5 ) are used in order to assist in the prediction of patient outcome, to provide information for patients who are at risk of early relapse or progression and to aid in developing risk stratification tools.…”

Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population

“…In a study from Mexico's National Cancer Institute, 5083 new cases with 2815 deaths due to NHL during 2015 were censored [25]. We documented 378 patients with NHL in the study period with an M:F ratio of 1.4:1.…”

“…It affects approximately 5000 new patients in Latin America each year [2], whereas in Mexico, 935 cases were reported in 2003 [35]. In a recent report from the National Cancer Institute in Mexico, 1677 new cases of HL with 675 deaths were documented during 2015 [25]. We recently reported data on HL patients in Northeast México, finding a high rate of refractory disease, advanced stages at diagnosis and decreased survival [36].…”

A Prognostic Score for Survival in Patients Older than 65 Years with Diffuse Large B-Cell Lymphoma

“…Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of NHL. Although this disease is potentially curable, the outcome of patients ≥ 65 years old with DLBCL has been reported by different authors as suboptimal [4][5][6] . The presence in this group of patients of comorbidities, impaired bone marrow function, and altered drug metabolism may increase the number of treatment-related complications, as well as hospitalization and mortality rates.…”